In 2022 it received EMA approval for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an IMiD, a PI and an anti‐CD38 antibody, and FDA approval to treat patients who have received at least four prior lines of therapy, including a PI, an IMiD, and an anti‐CD38 monoclonal antibody. This evidence concerns the gene CD38 and plasma cell myeloma.